<DOC>
	<DOC>NCT00582634</DOC>
	<brief_summary>- To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer - To evaluate the time to progression and overall survival - To evaluate toxicities of this chemotherapy combination in the adjuvant setting - To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen</brief_summary>
	<brief_title>Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Stage IB to IIIA nonsmall cell lung cancer completely resected within 4 to 8 weeks of initiating treatment on study Performance Status ECOG 0 or 1 Peripheral neuropathy: &lt; grade 1 Adequate blood cell counts Adequate liver and hepatic function Women of childbearing potential must have a negative pregnancy test. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter Patients with a history of severe hypersensitivity reaction to DocetaxelÂ® or other drugs formulated with polysorbate 80. Women who are breastfeeding. Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively) Uncontrolled cardiac disease or uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>adjuvant</keyword>
	<keyword>cisplatin</keyword>
	<keyword>docetaxel</keyword>
</DOC>